https://bibliome.ai/ is a resource for looking up specific genome variants and their references in the literature and open-access databases.
when i click through to references they’re often inaccurate (they are claimed to reference a variant that they do not, in fact, contain) but tbh this is also true of Google Search and Google Scholar when it comes to rare variants.
links 11/6/2024: https://roamresearch.com/#/app/srcpublic/page/11-06-2024
https://angrystaffofficer.com/2018/09/19/if-the-hoth-crash-was-an-air-force-investigation/
this taught me the phrase “mishap pilot”
https://pmc.ncbi.nlm.nih.gov/articles/PMC5656536/ this is measles virus used against relapsed multiple myeloma; one complete response out of 32 patients.
https://www.nature.com/articles/s41375-020-0828-7.pdf the one patient with the CR had strong T-cell responses to measles virus proteins. suggests that when this works it’s via immune response.
https://ajronline.org/doi/pdf/10.2214/AJR.09.3672 it works on mouse pancreatic cancer
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.509 seems to be able to treat bladder cancer?
https://pmc.ncbi.nlm.nih.gov/articles/PMC3018921/ blocks medulloblastoma growth in mice
https://en.wikipedia.org/wiki/CD46 the receptor for measles virus is also frequently expressed by cancer cells
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1095219/full targeting CDKs in sarcomas—there are some clinical trials happening
https://ascopubs.org/doi/abs/10.1200/PO.24.00219 palcociclib: one partial response out of 42 sarcoma patients
https://aacrjournals.org/clincancerres/article/29/17/3484/728559 suggestive in-vitro/animal evidence
targeting FGFRs in advanced solid tumors with FGFR mutations/overexpression: https://dial.uclouvain.be/pr/boreal/object/boreal%3A285422/datastream/PDF_01/view
3% complete response, 25% partial response with erdafitinib
https://pmc.ncbi.nlm.nih.gov/articles/PMC8231807/ FGFR inhibitors are typically toxic
MPNSTs cluster into two distinct types of genomic alteration with different drug vulnerabilities https://www.nature.com/articles/s41467-023-38432-6.pdf
targeting MDM2 in advanced solid tumors: there’s a trial. https://clinicaltrials.gov/study/NCT03611868
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9517 2 complete responses in melanoma, 1 PR each in liposarcoma, urothelial, and NSCLC, but none in MPNST.
http://www.annclinlabsci.org/content/46/6/627.full it’s being explored as a target in cancer
https://www.sciencedirect.com/science/article/abs/pii/S0959804920313228 21% partial response in soft tissue sarcoma to a XPO1 inhibitor + chemo
review article on XPO1 inhibition https://www.nature.com/articles/s41571-020-00442-4
https://www.centauri-dreams.org/2024/11/05/vegas-puzzling-disk/ the star Vega looks like it has a disc but no planets
https://www.nature.com/articles/s41598-024-58899-7 CD74 in cancer is an indicator for M1 macrophage infiltration, across cancer types
https://bibliome.ai/ is a resource for looking up specific genome variants and their references in the literature and open-access databases.
when i click through to references they’re often inaccurate (they are claimed to reference a variant that they do not, in fact, contain) but tbh this is also true of Google Search and Google Scholar when it comes to rare variants.